This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Bacillus calmette-guerin substrain connaught live antigen
- DrugBank Accession Number
- DB10804
- Background
Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). The solution contains live, attenuated strain of Mycobacterium bovis. It is prepared from the Connaught strain of Bacillus Calmette and Guérin.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- BCG, Live, Connaught Strain
Pharmacology
- Indication
Indicated for intravesical use in the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR).
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Carcinoma in situ of urinary bladder •••••••••••• •••••••• Prophylaxis of Carcinoma in situ of urinary bladder •••••••••••• •••••••• Prophylaxis of Primary stage t1 papillary tumors •••••••••••• ••••••••••••• ••••••••• ••••• Prophylaxis of Primary stage ta papillary tumors •••••••••••• ••••••••••••• ••••••••• ••••• Prophylaxis of Recurrent stage t1 papillary tumors •••••••••••• ••••••••••••• ••••••••• ••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Abacavir. Abatacept The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Abatacept. Acyclovir The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Acyclovir. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Bacillus calmette-guerin substrain connaught live antigen. Adefovir dipivoxil The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Adefovir dipivoxil. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Bcg Vaccine (freeze-dried) Powder, for solution 0.1 mg / 0.1 mL Intradermal Sanofi Pasteur Limited 1961-12-31 2015-08-18 Canada 
Immucyst Powder, for suspension 81 mg / vial Intravesical Sanofi Pasteur Limited 1990-12-31 2018-01-31 Canada Theracys Injection, powder, lyophilized, for solution 81 mg/3mL Intravesical Sanofi Pasteur Limited 2011-07-22 2017-05-08 US 
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5H5854UBMZ
- CAS number
- Not Available
References
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Active Not Recruiting Treatment Bladder Cancer 1 somestatus stop reason just information to hide 3 Completed Prevention Coronavirus Disease 2019 (COVID‑19) / COVID 1 somestatus stop reason just information to hide 3 Completed Treatment Bladder Cancer 1 somestatus stop reason just information to hide 3 Recruiting Treatment Bladder Cancer 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder, for solution Intradermal 0.1 mg / 0.1 mL Powder, for suspension Intravesical 81 mg / vial Injection, powder, lyophilized, for solution Intravesical 81 mg/3mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 01, 2015 20:04 / Updated at September 15, 2024 01:12